OBJECTIVES: @entity5721 after cardiopulmonary bypass is known to provoke an inflammatory response, which can be attenuated with @entity134 pretreatment. Cardiopulmonary bypass is also known to stimulate apoptosis. Induction of the cellular apoptotic cascade occurs via interaction between two membrane receptors: Fas and @entity12 . Both molecules also exist in soluble forms, whose significance remains undetermined; however, both may have a proinflammatory role. We aimed to document the temporal profile of soluble Fas and soluble @entity12 after cardiopulmonary bypass and to investigate whether @entity134 pretreatment alters this response. METHODS: The study was of a non-randomized, non-blinded, prospective nature. Twenty-seven @entity1 were monitored prospectively, of whom 13 received @entity619 at induction of anesthesia. Soluble Fas, soluble @entity12 , and @entity650 were measured from induction of anesthesia until 24 hours after admission to the intensive care unit. Data on clinical and laboratory variables were also collected at the same time intervals. RESULTS: As expected, @entity619 pretreatment attenuated @entity650 release and the clinical systemic inflammatory response after bypass. Soluble Fas showed a remarkably similar profile to @entity650 , in terms of temporal release and attenuation with @entity230 . There was also a correlation between maximum soluble Fas and markers of capillary leak (colloid requirement and drain loss). Conversely, soluble @entity12 release was unchanged by cardiopulmonary bypass and @entity134 administration. However, @entity1 with higher soluble @entity12 levels exhibited a more dramatic drop and delayed recovery in monocyte count, consistent with the role of this molecule in apoptosis. CONCLUSIONS: Release of soluble Fas and soluble @entity12 follows a markedly different temporal profile after cardiopulmonary bypass. The similarity between soluble Fas and @entity650 , together with the attenuation of both with @entity230 , may suggest a role for soluble Fas as a proinflammatory marker.

Soluble Fas may be a proinflammatory marker after cardiopulmonary bypass in XXXX .

@entity1 :: ('9606', 'Species') :: ['patients', 'infants'] @entity650 :: ('3569', 'Gene') :: ['interleukin 6'] @entity5721 :: ('MESH:D015427', 'Disease') :: ['Ischemia-reperfusion injury'] @entity134 :: ('CHEBI:35341', 'Chemical') :: ['steroid'] @entity12 :: ('356', 'Gene') :: ['Fas ligand'] @entity619 :: ('MESH:D003907', 'Chemical') :: ['dexamethasone'] @entity230 :: ('MESH:D013256', 'Chemical') :: ['steroids']
@entity1 :: (9606,Species) :: ['children']
